Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | NCI-H929 is a human multiple myeloma (plasma cell myeloma) cell line established in 1986 by A.F. Gazdar and his colleagues. This cell line was isolated from the pleural effusion of a 62-year-old Caucasian female patient diagnosed with end-stage multiple myeloma. NCI-H929 cells grow in suspension as single, round cells, occasionally forming loose aggregates or transiently adhering weakly to plastic culture surfaces. It is a globally recognized, landmark in vitro model for the study of plasma cell malignancies. The cell line naturally harbors the characteristic t(4;14)(p16.3;q32.3) chromosomal translocation, which leads to the dysregulated expression of the FGFR3 and NSD2 (MMSET) genes—a molecular subtype representing a high-risk category of multiple myeloma. Globally, it serves as an indispensable preclinical research tool for investigating the mechanisms of B-cell maturation, the networks underlying resistance to proteasome inhibitors, and for screening next-generation immunotherapies (such as CAR-T cells and BCMA-targeted agents). |
| Tissue | Myeloid / Blood; derived from metastatic site (Pleural Effusion) |
| Disease | Multiple Myeloma / Plasma Cell Myeloma |
| Morphology | Lymphoblast-like / Plasma cell-like; round floating cells |
| Gender | Female |
| Age | 62 years |
| Product Format | Frozen |
| Growth Mode | Suspension (with a minor fraction of cells displaying loose/transient attachment to the vessel floor) |
| Biosafety Level | 1 (Biosafety classification is based on standard global cell repository criteria) |
| Applications | 1. Cutting-edge models for investigating the pathobiology of high-risk t(4;14)-positive multiple myeloma; 2. Preclinical drug screening for proteasome inhibitors and immunomodulatory agents; 3. Assessment of target expression levels and cytotoxic efficacy for BCMA-targeted therapies, bispecific antibodies, and CAR-T constructs; 4. Investigation of downstream signaling pathways driving the survival of neoplastic plasma cells, as well as their interactions with the bone marrow microenvironment; 5. Establishment of systemic or localized multiple myeloma xenograft models in highly immunodeficient mice (e.g., NSG or SCID). |
| Shipped In | Dry ice |
| Storage Temperature | −196°C (Liquid nitrogen vapor phase only) |
| Characteristics | |
| Tumorigenic | Yes, forms tumors in immunocompromised mice. |
| Secretory Profile | Synthesizes and secretes a unique combination of immunoglobulin chains: positive for intact IgA kappa (κ) chains, accompanied by the secretion of excess free kappa light chains. Lambda (λ) chains are negative. |
| Karyotype | It presents a human hyperdiploid/aneuploid karyotype, with a modal chromosome number typically ranging between 50 and 54. It is characterized by highly complex and recurrent structural rearrangements, commonly observed in advanced plasma cell malignancies. |
| Genetic Profile | 1. Translocation: Canonical t(4;14)(p16.3;q32.3) placing the FGFR3 and NSD2 (MMSET) oncogenes under the control of the IGH enhancers. 2. TP53 Status: Wild-type (retains functional p53 signaling pathways). 3. EBV Status: EBV-negative (Epstein-Barr Virus negative). |
| Immunophenotype | Strongly positive for CD38, CD138 (Syndecan-1), and BCMA (CD269); Negative for surface pan-B markers CD19 and CD20, matching the differentiated myeloma phenotype. |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Subculturing | 1. Since these cells grow primarily in suspension, enzymatic digestion (trypsinization) is entirely unnecessary. 2. Gently shake the culture vessel to ensure the suspension is thoroughly mixed, then transfer the medium into a sterile conical centrifuge tube. 3. Centrifuge the suspension at approximately 200-300 × g (or 1000 rpm) for 5 minutes. 4. Carefully aspirate the supernatant, ensuring that the cell pellet remains completely undisturbed. 5. Uniformly resuspend the cell pellet in pre-warmed, fresh complete medium. 6. Aliquot the cells into new culture flasks. Critical Density Window: The growth of NCI-H929 cells is highly sensitive to density; if diluted excessively, the cells will rapidly undergo apoptosis. |
| Medium Renewal | Every 2 to 4 days depending on cell concentration and visual color shifts of the medium. |
| Subcultivation Ratio | Split optimal suspension cultures by adding fresh medium or allocating to new vessels at a ratio of 1:2 to 1:3. |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | 90% Complete culture medium (containing 20% FBS) + 10% DMSO (or 50% RPMI 1640 + 40% FBS + 10% DMSO) |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RR00914 | GFP Reporter Cell Line - NCI-H929 | Inquiry |
| CSC-RR00967 | Luciferase Reporter Cell Line - NCI-H929 | Inquiry |
| CSC-RR01226 | Nluc Reporter Cell Line - NCI-H929 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.